REV Group price target raised to $22 from $20 at Baird 03/10 REVG Baird analyst Mircea Dobre raised the firm's price target on REV Group to $22 from $20 and keeps an Outperform rating on the shares. Dobre said that the company is having a "solid start" to fiscal 2021, as F&E and RV achieved organic sales growth and all three segments improved EBITDA margins. The analyst added that he sees longer-term potential in the high $20s.
-Piper likes setup for Akebia shares after vadadustat submission 09:01 AKBA Piper Sandler analyst Christopher Raymond continues to like the setup for shares of Akebia Therapeutics after the company submitted a New Drug application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis. The analyst believes current share levels reflect "essentially zero credit" for vadadustat, "even in the relatively de-risked dialysis setting." He keeps an Overweight rating on Akebia shares with an $8 price target.
Oh. Says they make Fleetwood RV's in that paragraph you posted. Well, either way, they're junk. The Fleetwoods. Hey this simulatar stock, VTSI ... as much as I hate these kind of stocks, this one might actually be worth a look. They only have 7.8M M shares outstanding. Float is 7.3MM. If my data is correct. We'll put this one on the back burner for some DD. Its not going anywhere. No rush.
AKBA-$ 3.10--> $8 pt! This same analyst was pounding the table before a perceived delay in the news that came today-- 2/25 Akebia selloff on NDA timing 'wholly misplaced,' says Piper Sandler 02/25 AKBA Piper Sandler analyst Christopher Raymond recommends using today's post-earnings selloff in shares of Akebia Therapeutics as a buying opportunity. Auryxia sales of $34.6M beat estimates and though management highlighted Covid-19's impact on the renal population as a headwind into 2021, this is not an Auryxia-specific issue, Raymond tells investors in a research note titled "Buyers on Weakness; Hand-Wringing Over Vada NDA Timing Wholly Misplaced." Further, for vadadustat, there is now clarity on the new drug application submission timing, expected mid-Q2, says the analyst. The stock selloff suggests some observers were expecting it sooner, notes Raymond, who says the timing is in line with his expectations. He believes that at current levels, the stock reflects minimal credit for vadadustat even in dialysis. Raymond keeps an Overweight rating on Akebia with an $8 price target. Feb 8th stk was $5<----- delay Today--> $3.15